Tekla Life Sciences Investors Stock

$13.16

0.84% yesterday

NYSE, Jul 17, 10:10 pm CET

ISIN

US87911K1007

Symbol

HQL

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Finances

Industry

Financial service provider

Overview Dividends Analysts Charts News Strategies

Tekla Life Sciences Investors Stock price

$13.16

-5.76 30.45% 5Y

NYSE, Closing price Thu, Jul 17 2025

+0.11 0.84%

ISIN

US87911K1007

Symbol

HQL

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Finances

Industry

Financial service provider

Key metrics

Basic

Market capitalization

$370.4m

Enterprise Value

$370.4m

Net debt

$0.0

Cash

Shares outstanding

29.0m

Valuation (TTM | estimate)

P/E

negative | -

P/S

113.3 | -

EV/Sales

113.3 | -

EV/FCF

negative

P/B

0.9

Dividends

DPS

$0.90

Yield 1Y | 5Y

6.9% | 9.0%

Growth 1Y | 5Y

-51.6% | -10.2%

Payout 1Y | 3Y

61.2% | -2,245.0%

Increased

0 Years

Financials (TTM | estimate)

Revenue

$3.3m | -

EBITDA

- | -

EBIT

$-2.7m | -

Net Income

$-12.0m | -

Free Cash Flow

$-37.4m

Growth (TTM | estimate)

Revenue

-10.2% | -

EBITDA

- | -

EBIT

-41.0% | -

Net Income

-130.8% | -

Free Cash Flow

Financial Health

Equity Ratio

99.8%

Return on Equity

18.5%

ROCE

-0.7%

ROIC

Debt/Equity

0.0

EPS

$-0.4

FCF per Share

$-1.3

Short interest

Employees

Rev per Employee

As a Free StocksGuide user, you can view scores for all 7,004 stocks worldwide.

Get Started for Free Today

Tekla Life Sciences Investors Stock Analysis

Unlock Scores for Free

??

Financial data from Tekla Life Sciences Investors

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	3.27 3.27	10% 10% 100%
- Direct Costs	5.84 5.84	18% 18% 179%
Gross Profit	-2.57 -2.57	93% 93% -79%
- Selling and Administrative Expenses	0.01 0.01	98% 98% 0%
- Research and Development Expense	- -	- -
EBITDA	- -	- -
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	-2.65 -2.65	41% 41% -81%
Net Profit	-12 -12	131% 131% -367%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Tekla Life Sciences Investors Stock News

Neutral

PRNewsWire

●

17 days ago

ABERDEEN INVESTMENTS U.S. CLOSED-END FUNDS ANNOUNCE DISTRIBUTION PAYMENT DETAILS

PHILADELPHIA , June 30, 2025 /PRNewswire/ -- The Aberdeen Investments U.S. Closed-End Funds (NYSE: ASGI, HQH, HQL, IFN, THQ), (NYSE American: IAF) (the "Funds" or individually the "Fund"), today announced that the Funds paid the distributions noted in the table below on June 30, 2025, on a per share basis to all shareholders of record as of June 23, 2025 (ex-dividend date June 23, 2025). The...

Positive

Seeking Alpha

●

23 days ago

CEF Insights: The Future Of Healthcare Investing

Groundbreaking AI-powered initiatives are set to transform the healthcare landscape, potentially revolutionizing cancer research and healthcare investing. Aberdeen Investments' four healthcare-focused closed-end funds meet various investor needs: THQ/THW for income and stability, HQH/HQL for growth and innovation exposure. Jason Akus, Portfolio Manager and Head of Healthcare Investments with Ab...

Positive

Seeking Alpha

●

about one month ago

HQL: Positive Outlook Due To Increased Healthcare Spending

I maintain my buy rating on HQL due to its attractive 14% yield, discounted valuation, and long-term healthcare growth outlook. Despite recent NAV declines and inconsistent income, HQL's performance is tied to macro conditions, not internal flaws, and should improve as the sector rebounds. HQL's diversified biotech-heavy portfolio, lack of leverage, and simple strategy offer stability and upsid...

More Tekla Life Sciences Investors News

Company Profile

Tekla Life Sciences Investors operates as a closed-end investment fund or Investment trust. The firm engages in the investment in the life sciences industry. It invests in biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals and healthcare information technology and services. The company was founded on February 20, 1992 and is headquartered in Boston, MA.

Head office	United States
CEO	Dan Omstead
Founded	1992
Website	www.teklacap.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now